Prostate Cancer

An assay for nuclear-localized androgen receptor splice variant 7 protein in circulating tumor cells identified patients with metastatic castration-resistant prostate cancer who had better outcomes from treatment with taxanes, and those who did better with androgen receptor-signaling inhibitors.

The FDA has approved enzalutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses imaging modalities in prostate cancer.

Evan Ya-Wen Yu, MD, discusses the evolution of treatment for patients with castration-sensitive prostate cancer and how he decides between treatment with abiraterone and docetaxel for this population.

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the exciting abstracts in prostate cancer that were presented at the 2018 ASCO Annual Meeting.

Scott Samuelson, MD, discusses frontline treatment of patients with prostate cancer and subsequent sequencing.

Benjamin Maughan, MD, PharmD, instructor, Division of Medical Oncology, Huntsman Cancer Institute, discusses enzalutamide (Xtandi) plus radium-223 (Xofigo) in metastatic castration-resistant prostate cancer.

Andy Hahn, MD, discusses the ongoing debate between abiraterone and docetaxel and the optimal patient selection for each agent in patients with metastatic hormone-sensitive prostate cancer.

Several studies presented at this year’s American Urological Association meeting underscored the value of multiparametric magnetic resonance imaging in the diagnosis and management of prostate cancer.

Andy Hahn, MD, resident, University of Utah School of Medicine, discusses abiraterone acetate (Zytiga) versus docetaxel in the treatment of patients with prostate cancer.

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment intensification in patients with metastatic castration-sensitive prostate cancer.

Cryoablation may help men whose prostate cancer recurs after radiation therapy avoid or delay retreatment with androgen deprivation therapy.

Veda Giri, MD, associate professor, Thomas Jefferson University Hospital, discusses genes that are associated with a risk of developing prostate cancer.

Patients younger than 65 years experienced net cancer costs that were higher for breast, colorectal, lung, and prostate cancer compared with patients who were 65 years and older.

Scott Samuelson, MD, medical oncologist, Utah Cancer Specialists, on frontline treatment of patients with prostate cancer and subsequent sequencing.

The use of PARP inhibitors in patients with a variety of tumor types is backed by a growing body of research, and there is now strong justification for clinical trials of these agents in patients with prostate cancer.

Moving radium-223 (Xofigo) up in the treatment paradigm for patients with prostate cancer could provide better outcomes and longer survival, according to Richard G. Stock, MD.

Raoul S. Concepcion, MD, FACS, discusses the importance of research opportunities for residents.

Susan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses overall survival between African-American and Caucasian men with metastatic castration-resistant prostate cancer.

Benjamin Maughan, MD, PharmD, instructor, Division of Medical Oncology, Huntsman Cancer Institute, discusses the combination of abiraterone acetate (Zytiga) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer.

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses how comorbidities factor into treatment choice for patients with castration-sensitive prostate cancer.

Combining olaparib (Lynparza) with abiraterone acetate (Zytiga) reduced the risk of disease progression or death by 35% compared with abiraterone alone in pretreated patients with metastatic castration-resistant prostate cancer.

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses findings with PARP inhibitors in prostate cancer.

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the results of the prospective multicenter Abi Race trial, which compared outcomes of African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (Zytiga) and prednisone.